Market Overview:
The global ultra-low molecular weight heparin (ULMWH) market is expected to register a CAGR of 5.8% during the forecast period, 2018-2030. The market growth can be attributed to the increasing incidence of venous thromboembolism (VTE), rising geriatric population, and technological advancements in ULMWH products. However, the high cost of treatment and lack of awareness about ULMWH products are some factors that are restraining the growth of this market. Based on type, the global ULMWH market is segmented into oral and parenteral segments. The oral segment is expected to register a higher CAGR during the forecast period as compared to the parenteral segment owing to its ease of use and lower cost as compared to parenteral drugs. Based on application, the global ULMWH market is divided into treatment of VTE, complications associated with pregnancy such as preeclampsia/eclampsia, deep vein thrombosis (DVT), atrial fibrillation/flutter (AFib), and others including pulmonary embolism (PE) and stroke prevention in patients with AFib). Among these applications, VTE treatment held majority share in 2017 owing to high prevalence rate for VTE across different geographies worldwide.
 Industry Outlook.svg)
Product Definition:
Ultra-low molecular weight heparin (ULMWH) is a form of heparin that has a lower molecular weight than standard heparin. ULMWH is used to prevent blood clots in people who are at risk for blood clots, such as those who have had a heart attack or stroke.
Oral:
Oral is a form of administration through the mouth. It can be used with injections or as a preparation for injection. The drug is administered by mouth in two ways, either with or without water. In the case of warfarin, it should be given with water because if it's not then there may be problems like bleeding tendency and other adverse effects due to interaction between drugs and food substances which are normally found in blood.
Parenteral:
Parenteral is a route of administration used to introduce therapeutic agents into the body. The parenteral route of drug delivery is majorly used for drugs that are lipid-soluble and need to be administered intravenously. Parenteral drug delivery systems include syringes, vials, ampoules, and cartridges.
ULMWH Market by Geography (North America [The U.S.
Application Insights:
The treatment of venous thromboembolism (VTE) segment held the largest market share in 2017. VTE is a common medical condition that affects mostly older patients and those suffering from cancer, atrial fibrillation/flutter, or pulmonary embolism. The incidence of VTE is on the rise due to an increase in cancer cases and aging population across the globe. As per data published by International Agency for Research on Cancer (IARC), around 5-10% of hospitalized patients develop VTE after surgery every year globally.
In North America ULMWHs are used for treating complications of pregnancy such as deep vein thrombosis (DVT) & pulmonary hypertension as well as cardiopulmonary resuscitation (CPR). In addition, they are also used for various other conditions such as acute renal failure, postoperative pain management, and treatment refractory hypoxic-ischemic encephalopathy among others.
Regional Analysis:
North America dominated the global market in 2017. This can be attributed to the presence of key players, high healthcare expenditure and favorable reimbursement policies pertaining to ULMWHs. In addition, increasing incidence of VTE is also one of the major factors responsible for regional growth. For instance, according to a study published by National Center for Health Statistics (NCHS), in 2015 around 8.9 million women were diagnosed with VTE compared with 6.7 million in 2001 which represents an increase of 24%.
Asia Pacific is expected to witness lucrative growth over the forecast period owing to rising geriatric population and lifestyle-associated diseases such as cardiovascular disorders & hypertension that are prone Venous Thromboembolism (VTE).
Growth Factors:
- Increasing incidence of venous thromboembolism (VTE) and pulmonary embolism (PE)
- Rising geriatric population susceptible to VTE and PE
- Growing demand for prophylactic anticoagulants to prevent VTE and PE
- Technological advancements in ULMWH manufacturing process
- increasing healthcare expenditure
Scope Of The Report
Report Attributes
Report Details
Report Title
Ultra-low Molecular Weight Heparin (ULMWH) Market Research Report
By Type
Oral, Parenteral
By Application
Treatment of Venous Thromboembolism, Complications of Pregnancy, Cardioversion of Atrial Fibrillation/Flutter
By Companies
Hepalink, Changshan Pharm, Qianhong Bio-pharma, Opocrin, Pfizer, Aspen Oss, King-friend Biochemical Pharmaceutical, Bioiberica, Dongcheng Biochemicals, Jiulong Biochemicals, Hepalink, Xinbai, Yino Pharma Limited, Deebio
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
232
Number of Tables & Figures
163
Customization Available
Yes, the report can be customized as per your need.
Global Ultra-low Molecular Weight Heparin (ULMWH) Market Report Segments:
The global Ultra-low Molecular Weight Heparin (ULMWH) market is segmented on the basis of:
Types
Oral, Parenteral
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Treatment of Venous Thromboembolism, Complications of Pregnancy, Cardioversion of Atrial Fibrillation/Flutter
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Hepalink
- Changshan Pharm
- Qianhong Bio-pharma
- Opocrin
- Pfizer
- Aspen Oss
- King-friend Biochemical Pharmaceutical
- Bioiberica
- Dongcheng Biochemicals
- Jiulong Biochemicals
- Hepalink
- Xinbai
- Yino Pharma Limited
- Deebio
 Market Overview.svg)
Highlights of The Ultra-low Molecular Weight Heparin (ULMWH) Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Oral
- Parenteral
- By Application:
- Treatment of Venous Thromboembolism
- Complications of Pregnancy
- Cardioversion of Atrial Fibrillation/Flutter
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Ultra-low Molecular Weight Heparin (ULMWH) Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
 Market Statistics.svg)
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
ULMWH is a type of heparin that has been designed to be more effective than other types of heparin. ULMWH is also known as ultra-low molecular weight heparin, low molecular weight heparin, or microheparins.
Some of the major companies in the ultra-low molecular weight heparin (ulmwh) market are Hepalink, Changshan Pharm, Qianhong Bio-pharma, Opocrin, Pfizer, Aspen Oss, King-friend Biochemical Pharmaceutical, Bioiberica, Dongcheng Biochemicals, Jiulong Biochemicals, Hepalink, Xinbai, Yino Pharma Limited, Deebio.
The ultra-low molecular weight heparin (ulmwh) market is expected to grow at a compound annual growth rate of 5.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Ultra-low Molecular Weight Heparin (ULMWH) Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Ultra-low Molecular Weight Heparin (ULMWH) Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Ultra-low Molecular Weight Heparin (ULMWH) Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Ultra-low Molecular Weight Heparin (ULMWH) Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Ultra-low Molecular Weight Heparin (ULMWH) Market Size & Forecast, 2020-2028
4.5.1 Ultra-low Molecular Weight Heparin (ULMWH) Market Size and Y-o-Y Growth
4.5.2 Ultra-low Molecular Weight Heparin (ULMWH) Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Oral
5.2.2 Parenteral
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Treatment of Venous Thromboembolism
6.2.2 Complications of Pregnancy
6.2.3 Cardioversion of Atrial Fibrillation/Flutter
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Ultra-low Molecular Weight Heparin (ULMWH) Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Ultra-low Molecular Weight Heparin (ULMWH) Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Oral
9.6.2 Parenteral
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Treatment of Venous Thromboembolism
9.10.2 Complications of Pregnancy
9.10.3 Cardioversion of Atrial Fibrillation/Flutter
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Oral
10.6.2 Parenteral
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Treatment of Venous Thromboembolism
10.10.2 Complications of Pregnancy
10.10.3 Cardioversion of Atrial Fibrillation/Flutter
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Oral
11.6.2 Parenteral
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Treatment of Venous Thromboembolism
11.10.2 Complications of Pregnancy
11.10.3 Cardioversion of Atrial Fibrillation/Flutter
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Oral
12.6.2 Parenteral
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Treatment of Venous Thromboembolism
12.10.2 Complications of Pregnancy
12.10.3 Cardioversion of Atrial Fibrillation/Flutter
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Oral
13.6.2 Parenteral
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Treatment of Venous Thromboembolism
13.10.2 Complications of Pregnancy
13.10.3 Cardioversion of Atrial Fibrillation/Flutter
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Ultra-low Molecular Weight Heparin (ULMWH) Market: Competitive Dashboard
14.2 Global Ultra-low Molecular Weight Heparin (ULMWH) Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Hepalink
14.3.2 Changshan Pharm
14.3.3 Qianhong Bio-pharma
14.3.4 Opocrin
14.3.5 Pfizer
14.3.6 Aspen Oss
14.3.7 King-friend Biochemical Pharmaceutical
14.3.8 Bioiberica
14.3.9 Dongcheng Biochemicals
14.3.10 Jiulong Biochemicals
14.3.11 Hepalink
14.3.12 Xinbai
14.3.13 Yino Pharma Limited
14.3.14 Deebio
